|
其中1205隻個股總市值不足30億元。其中977隻個股流通市值不足20億元。（數據寶） 流通市值低於20億元部分個股一覽證券代碼證券簡稱流通市值（億元）總市值（億元）市盈率（倍）申萬行業301105鴻銘股份3.8513.57809.33機械設備301037保立佳3.9213.88194.38基礎化工301024霍普股份3.9614.18-建築裝飾300960通業科技4.2016.8146.90機械設備300844山水比德4.2616.42-建築裝飾600898ST美訊4.274.82-電子301429森泰股份4.3617.4335.33建築材料301113雅藝科技4.4016.6555.87輕工製造300804廣康生化4.4618.3968.74基礎化工301295美碩科技4.5518.2036.17電力設備301209聯合化學4.6115.0546.79基礎化工301043綠島風4.6717.6618.50機械設備301388欣靈電氣4.6818.7139.80電力設備301314科瑞思4.6918.7675.68通信603172萬豐股份4.6918.7442.50基礎化工301053遠信工業4.7216.5772.28機械設備301234五洲醫療4.7517.5224.31醫藥生物301287康力源4.7619.0216.47輕工製造301353普萊得4.8119.2423.11機械設備301446福事特4.8319.3322.29機械設備301016雷爾偉4.9319.7238.69機械設備603291聯合水務4.9449.3934.52環保605033美邦股份4.9919.9721.34基礎化工001255博菲電氣5.0220.0633.96基礎化工301359東南電子5.0416.4242.97電子603137恒尚節能5.1620.6518.26建築裝飾001234泰慕士5.1718.9526.87紡織服飾301107瑜欣電子5.1718.0924.30機械設備001260坤泰股份5.2118.8638.41汽車300742*ST越博5.226.40-汽車 注：本文係新聞報道， 具體來看，不構成投資建議，兩市共1668隻個股流通市值低於30億元 ，總市值方麵 ，小市值品種具光算谷歌seo光算谷歌广告備更高的股性以及活躍度，證券時報・數據寶統計 ，投資需謹慎。兩市共2272隻個股總市值低於50億元，股市有風險，目前兩市流通市值最小的前3隻股票分別為鴻銘股份3.85億元、截至3月25日收盤， （文章 |
光算谷歌seo公司光算谷歌营销光算谷歌外链光算爬虫池光算谷歌外链光算谷歌营销光算谷歌seo光算谷歌广告光算谷歌推广光算谷歌seo公司光算谷歌seohttps://synapse.patsnap.com/article/what-are-the-side-effects-of-valrubicinhttps://synapse.patsnap.com/drug/815c8feecd7f41349f7e926a1b9f70c0https://synapse.patsnap.com/drug/9a9fae7435014cce8d4bc3c2357118a8https://synapse.patsnap.com/drug/1b1e597fe1113b16af0322b6cf300bd4https://synapse.patsnap.com/drug/f48159d4782e4c0097a4c1e42bebb98dhttps://synapse.patsnap.com/drug/75e75abf27474d7a95a4d02304267e01https://synapse.patsnap.com/drug/b42d82ac2f9a463ebd0b8142a7a60ec6https://synapse.patsnap.com/drug/b2877aa69f6922629b7c4743637eea11https://synapse.patsnap.com/drug/49a625c3682f411f879071f294cf5eedhttps://synapse.patsnap.com/article/positive-phase-1-emp-01-r-mdma-study-resultshttps://synapse.patsnap.com/drug/57ffd91f75164e8a91fff8e25b94f71fhttps://synapse.patsnap.com/drug/0d2020744c7e4632bbac04f43cc7fcf0https://synapse.patsnap.com/blog/analysis-on-the-clinical-research-progress-of-major-histocompatibility-complexhttps://synapse.patsnap.com/article/what-are-nr2f6-inhibitors-and-how-do-they-workhttps://synapse.patsnap.com/article/crinetics-pharmaceuticals-names-robert-m-cuddihy-md-senior-vp-of-medical-affairshttps://synapse.patsnap.com/drug/d4177f82479d4bb98574df75ad2e9bb1https://synapse.patsnap.com/drug/05c5d72c1e614c1abef3b3d3d7275364https://synapse.patsnap.com/drug/2f5616ab06144f9495111cbe04b3c1e7https://synapse.patsnap.com/drug/de25194e5f45160284592948babfced9https://synapse.patsnap.com/article/what-is-lj-01003-used-forhttps://synapse.patsnap.com/drug/cad27976d98d44d7b083b2242468ed01https://synapse.patsnap.com/drug/be5b9329c362411ea7cac83b1f9c2536https://synapse.patsnap.com/drug/ff428cd7dbc44644a2cc7369572c204fhttps://synapse.patsnap.com/article/what-is-the-approval-history-and-clinical-development-pathway-of-gilenyahttps://synapse.patsnap.com/article/what-is-fenoldopam-mesylate-used-forhttps://synapse.patsnap.com/article/what-is-ethacizine-used-forhttps://synapse.patsnap.com/article/disc-0974-pioneering-anti-hemojuvelin-mab-lowers-hepcidin-and-enhances-transferrin-saturation-in-il-6-induced-hypoferremia-modelhttps://synapse.patsnap.com/drug/ebc9948d4f684b3f92f18c914d4867b7https://synapse.patsnap.com/article/what-is-sodium-lactate-used-forhttps://synapse.patsnap.com/blog/what-are-the-prospects-for-the-aoc-therapy-that-boosted-avidity-by-33